A new clinical trial from the University of Leeds is testing omega-3 capsules in patients who have bowel cancer which has spread to the liver, to see if it can stop the cancer returning after surgery.
Promising results in an earlier smaller trial showed that providing patients with 2g per day of the omega-3, called EPA, for around a month prior to surgery led to a 30 per cent increase in survival after 18 months.
Researchers at the University of Leeds are building on this past work by launching a larger clinical trial, recruiting 450 patients who are undergoing surgery for bowel cancer which has spread to the liver, known as secondary liver cancer. The first Leeds patient has just been recruited to the trial in Leeds Teaching Hospitals NHS Trust.
The trial is investigating whether a highly purified form of the omega-3 EPA could be an effective way to stop cancer returning after surgery, and is funded by Yorkshire Cancer Research.
Professor Mark Hull, from the University of Leeds’ Institute of Biomedical and Clinical Sciences and Leeds Teaching Hospitals, is leading the trial, which involves several hospitals from around the country, including Leeds, Sheffield and Southampton.
Article originally posted at